Advertisement
RPRX vs VRTX
Which Stock Would AI Choose? Royalty Pharma (RPRX) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- Contrasting business models: RPRX collects royalties across a diversified portfolio of approved therapies, while VRTX develops and commercializes its own drugs, led by a dominant cystic fibrosis (CF) franchise.
- Relative momentum favors RPRX: RPRX has climbed roughly 30% year to date and recently traded near a 52-week high, whereas VRTX has shown choppier performance as investors weigh pipeline catalysts against a premium valuation.
- Different risk profiles: RPRX offers diversified cash flows and a quarterly dividend, while VRTX carries higher upside but also more concentrated, catalyst-driven risk.
- Tickeron AI Verdict: Based on trend consistency, stability, and diversified positioning, Tickeron's AI currently favors RPRX over VRTX in this comparison.
- For deeper coverage of each name, explore RPRX Major News and RPRX Today's Price Move, as well as VRTX Major News and VRTX Today's Price Move.
- To see how AI-driven strategies are positioning across the market, visit the Trending AI Robots page.
Introduction
Investors evaluating the healthcare sector often face a choice between a cash-flow-rich royalty aggregator and a high-growth drug developer. RPRX (Royalty Pharma plc) and VRTX (Vertex Pharmaceuticals Incorporated) sit at opposite ends of that spectrum despite operating in the same biopharmaceutical ecosystem. This stock comparison is relevant for traders seeking relative performance signals, income-oriented investors drawn to diversified royalty streams, and growth investors weighing pipeline catalysts. The two companies are also directly connected: RPRX holds royalties on the cystic fibrosis franchise marketed by VRTX, making their market positioning unusually intertwined.
RPRX Overview and Recent Performance
RPRX is the world's largest buyer of biopharmaceutical royalties, generating income from a broad basket of approved therapies across oncology, immunology, neuroscience, and rare diseases. Rather than developing drugs itself, it provides capital to biopharma partners in exchange for future royalty streams. In recent weeks, sentiment has been constructive as the company reported double-digit growth in royalty receipts, raised its full-year 2026 guidance for a second consecutive quarter, and received an investment-grade credit rating upgrade to BBB. The stock has climbed roughly 30% since the start of the year and recently traded near a 52-week high. A recurring quarterly dividend of $0.235 per share adds an income component, while headwinds from the loss of exclusivity on certain older products have been offset by strength in newer royalty assets.
VRTX Overview and Recent Performance
VRTX is a global biotechnology company whose cystic fibrosis portfolio generates the bulk of its revenue, led by Trikafta/Kaftrio and the newer once-daily Alyftrek. The company is actively diversifying beyond CF through new products such as Journavx (suzetrigine), a non-opioid pain therapy, and Casgevy, a gene-editing treatment for blood disorders. Recent market activity has been shaped by pipeline news, including positive Phase 3 data for povetacicept in IgA nephropathy (a kidney disease), published in the New England Journal of Medicine, with an FDA decision expected in late 2026. The company also closed a roughly $10 billion acquisition to build an obesity-focused portfolio. Despite these catalysts, VRTX shares have been more volatile, reflecting investor debate over valuation and how quickly diversification will translate into durable growth.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies drawn from a much larger universe of AI-driven bots. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and target list of securities. Only the strategies deemed most suitable for current market conditions earn a place in this featured section, which is designed to help traders filter signal from noise. Whether a bot favors trend-following, swing trading, or longer-horizon positioning, the page gives users a way to compare approaches at a glance. Explore Trending AI Robots to see which strategies are currently leading the field.
Head-to-Head Comparison
The clearest contrast between these two names is how they generate value. RPRX functions as a capital allocator, spreading risk across many approved drugs and relying on contractual cash flows, which tends to produce steadier, more predictable results and supports a dividend. VRTX, by comparison, is an operator whose fortunes hinge on clinical success, regulatory approvals, and commercial execution, creating higher potential upside but also greater concentration risk. On growth drivers, VRTX offers more dramatic catalysts from its pipeline and new launches, while RPRX grows through new royalty acquisitions and research-and-development co-funding deals. Sector exposure also differs: VRTX is heavily weighted to rare and specialty diseases, whereas RPRX is diversified across multiple therapeutic areas and counterparties. On valuation, VRTX trades at a premium multiple that embeds future pipeline success, while RPRX carries a more modest valuation reflective of its steadier, lower-beta profile.
Tickeron AI Verdict
Weighing trend consistency, stability, and relative positioning, Tickeron's AI would currently lean toward RPRX. The stock's sustained uptrend, diversified cash-flow base, and recent guidance increases present a more consistent technical and fundamental picture than the more catalyst-dependent trajectory of VRTX. This assessment is probabilistic rather than definitive: VRTX retains a compelling long-term growth narrative that could reassert itself on favorable pipeline developments. In the current environment, however, the balance of trend stability and lower concentration risk favors the royalty model.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RPRX is a Hold and VRTX is a Buy.
Aroon Indicator for RPRX shows an upward move is likely
RPRX's Aroon Indicator triggered a bullish signal on November 05, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 268 similar instances where the Aroon Indicator showed a similar pattern. In 188 of the 268 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RPRX as a result. In 51 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
The Moving Average Convergence Divergence (MACD) for RPRX just turned positive on October 14, 2026. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in 30 of 50 cases over the following month. The odds of a continued upward trend are 60%.
RPRX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for RPRX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in 173 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.
RPRX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 15 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.386) is normal, around the industry mean (2.788). P/E Ratio (35.989) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (1.360) is also within normal values, averaging (9.059). Dividend Yield (0.014) settles around the average of (133.911) among similar stocks. P/S Ratio (12.870) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Momentum Indicator for VRTX turns positive, indicating new upward trend
VRTX saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 61 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for VRTX just turned positive on October 20, 2026. Looking at past instances where VRTX's MACD turned positive, the stock continued to rise in 41 of 59 cases over the following month. The odds of a continued upward trend are 69%.
VRTX moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VRTX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
Following a +5.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRTX advanced for three days, in 236 of 369 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for VRTX moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 25 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 58%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 63 cases where VRTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 44%.
VRTX broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VRTX entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. VRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.848) is normal, around the industry mean (2.788). P/E Ratio (31.605) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (1.939) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (10.449) is also within normal values, averaging (440.869).
RPRX | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 43 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 15 | 12 | |
SMR RATING 1..100 | 97 | 41 | |
PRICE GROWTH RATING 1..100 | 36 | 18 | |
P/E GROWTH RATING 1..100 | 15 | 37 | |
SEASONALITY SCORE 1..100 | 35 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RPRX's Valuation (91) in the Pharmaceuticals Major industry is in the same range as VRTX (91) in the Biotechnology industry. This means that RPRX’s stock grew similarly to VRTX’s over the last 12 months.
VRTX's Profit vs Risk Rating (12) in the Biotechnology industry is in the same range as RPRX (15) in the Pharmaceuticals Major industry. This means that VRTX’s stock grew similarly to RPRX’s over the last 12 months.
VRTX's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for RPRX (97) in the Pharmaceuticals Major industry. This means that VRTX’s stock grew somewhat faster than RPRX’s over the last 12 months.
VRTX's Price Growth Rating (18) in the Biotechnology industry is in the same range as RPRX (36) in the Pharmaceuticals Major industry. This means that VRTX’s stock grew similarly to RPRX’s over the last 12 months.
RPRX's P/E Growth Rating (15) in the Pharmaceuticals Major industry is in the same range as VRTX (37) in the Biotechnology industry. This means that RPRX’s stock grew similarly to VRTX’s over the last 12 months.
| RPRX | VRTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 48% | 2 days ago 58% |
| Stochastic ODDS (%) | 2 days ago 46% | 2 days ago 56% |
| Momentum ODDS (%) | 2 days ago 59% | 2 days ago 71% |
| MACD ODDS (%) | 2 days ago 60% | 2 days ago 69% |
| TrendWeek ODDS (%) | 2 days ago 56% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 68% |
| Advances ODDS (%) | 2 days ago 55% | 8 days ago 64% |
| Declines ODDS (%) | 4 days ago 49% | 4 days ago 44% |
| BollingerBands ODDS (%) | 2 days ago 60% | 2 days ago 57% |
| Aroon ODDS (%) | 2 days ago 70% | 2 days ago 44% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RPRX’s FA Score shows that 2 FA rating(s) are green while VRTX’s FA Score has 2 green FA rating(s).
- RPRX’s FA Score: 2 green, 3 red.
- VRTX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RPRX’s TA Score shows that 6 TA indicator(s) are bullish while VRTX’s TA Score has 5 bullish TA indicator(s).
- RPRX’s TA Score: 6 bullish, 4 bearish.
- VRTX’s TA Score: 5 bullish, 5 bearish.
Price Growth
RPRX (@Biotechnology) experienced а +2.49% price change this week, while VRTX (@Biotechnology) price change was +0.46% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.12%. For the same industry, the average monthly price growth was -4.39%, and the average quarterly price growth was -15.58%.
Reported Earning Dates
RPRX is expected to report earnings on Feb 16, 2027.
VRTX is expected to report earnings on Feb 09, 2027.
Industries' Descriptions
@Biotechnology (+7.12% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
RPRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To RPRX | 1D Price Change % | ||
|---|---|---|---|---|
| RPRX | 100% | +0.01% | ||
| AXON - RPRX | 48% Loosely correlated | -9.81% | ||
| INCY - RPRX | 47% Loosely correlated | -3.94% | ||
| VRTX - RPRX | 46% Loosely correlated | -1.19% | ||
| RIGL - RPRX | 40% Loosely correlated | -10.88% | ||
| EXEL - RPRX | 39% Loosely correlated | -5.55% | ||
More | ||||
VRTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with INCY. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then INCY could also see price increases.
| Ticker / NAME | Correlation To VRTX | 1D Price Change % | ||
|---|---|---|---|---|
| VRTX | 100% | +0.85% | ||
| INCY - VRTX | 47% Loosely correlated | +1.39% | ||
| RPRX - VRTX | 46% Loosely correlated | -0.40% | ||
| BMRN - VRTX | 45% Loosely correlated | -0.16% | ||
| EDIT - VRTX | 44% Loosely correlated | +0.78% | ||
| REGN - VRTX | 43% Loosely correlated | +0.16% | ||
More | ||||